LSPN Fall North America 2024

LSPN Fall 2024 took place on October 15-16 in San Francisco, gathering an unrivaled assembly of in-house patent counsel, intellectual property professionals, and industry leaders from pharmaceutical and biotechnology companies. The event offered a unique opportunity to explore critical developments in the life sciences sector and provided attendees with actionable insights into patent strategies, key legal decisions, and the broader political landscape impacting innovation.

Speakers represented some of the biggest names in life sciences and intellectual property, including Acuitas Therapeutics, Thermo Fisher Scientific, 10x Genomics, Gilead Sciences, Pfizer, Bristol Myers Squibb, Illumina, Mammoth Biosciences, IGM Biosciences, DLA Piper, Morgan Lewis, Mintz, Nutcracker Therapeutics, and many more.

WATCH: What we have learned so far and other thoughts on the new European patent litigation system

The Unified Patent Court (UPC) opened for business in June 2023. In this session, we will look at how UPC litigation has been shaping up over the last year, including practical tips based on our experiences so far.

WATCH: What are the latest challenges in patenting biologics, biosimilars, and bispecific antibodies?

29 October 2024

WATCH: Korean Biopharma's Global Expansion - Evolving Patent Strategies and Regulatory Landscape

29 October 2024

WATCH: The Unified Patent Court from the Frontline

In this session, Will James and Tim Harris will discuss their personal experiences litigating life sciences cases before the UPC. They will share their substantive and procedural insights, as well as strategic considerations and pitfalls to avoid.

WATCH: Jurisdictional overreach of foreign courts in patent disputes

Long-recognised, unwritten jurisdictional norms have seen questions of validity and infringement of registered IP rights reserved to the courts of the country of registration.

WATCH: How could AI patentability in Europe inform risk management discussions for investment in digital technology innovation within pharma?

Patents are key to ensuring continued investment in pharma R&D. What are the unique patent considerations for pharma/biotech patents and AI patents in Europe?

WATCH: Beyond the obvious: novelty, non-obviousness, and the inventive step in polymorph patents and beyond

In the world of intellectual property, securing patents for innovative ideas rests heavily on the criteria of novelty, non-obviousness, and the inventive step.

WATCH: Intersectionality of Intellectual Property with Licensing and Commercialization

In today's global marketplace, intellectual property (IP) rights are not merely legal tools but strategic assets that can significantly influence a product's lifecycle, from development to market.

WATCH: Beyond Patents-The evolving role of IP lawyers in life sciences

In an incredibly competitive and complex landscape, intellectual property is a critical asset for pharmaceutical and biotech companies.

WATCH: AI and machine learning in drug discovery - patenting AI-generated inventions

Machine learning can be an invaluable tool in drug discovery for target identification, compound screening, and predictive modeling. The use of AI can accelerate drug discovery timelines, reduce costs and enhance therapeutic outcomes.

WATCH: The new EU Clinical Trials Regulation – IP Considerations

As part of a lifecycle IP strategy for a therapeutic product, it can be important to protect inventions arising during the clinical development of the product.

WATCH: Navigating the PTAB frontier - shaping patent strategies for success

The dynamic landscape of patent law is continually influenced by evolving regulations and legal decisions, and one of the key areas at the forefront of these changes is the Patent Trial and Appeal Board (PTAB).

WATCH: The challenge of protecting patents and innovation - obviousness-type double patenting post In re Cellect

Obviousness-type double patenting can pose a significant challenge, as it can lead to unfair extensions of patent rights, and limit other’s abilities to build upon inventions, hindering further innovation.

WATCH: Essential considerations - patenting and clinical trials

There is an intricate intersection between patenting and clinical trials within the dynamic IP landscape in the life sciences industries. Safeguarding your innovation throughout the research process is critical, necessitating a careful balance between the need to file and when to file.

WATCH: European patent term extension (SPCs)

European Supplementary Protection Certificates (SPCs) are very different to US PTEs in several key respects. In this seminar, we'll run through strategies to secure maximal protection for approved pharmaceutical & biologic products in Europe.

WATCH: European IP landscape

There have been significant developments in the European patent landscape in 2024, not only at the UPC but at the European Patent Office.

WATCH: Strategies for success: patent drafting and application

Join us for a master class in patent drafting for successful applications to the USPTO. Our panel of experts will share invaluable insights into their best practices for success in patent drafting and application.

LSPN Fall North America 2024

Get up-to-date information on all our publications and events